Position in OMER
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
5 quarters on record
Common Shares in OMER Over Time
Shares Held
Position Value (USD)
Derivatives in OMER
reported options exposure · as of Jun 30, 2026CallValue
$0
CallShares
0
PutValue
$13,421,463
PutShares
1,411,300
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Affinity Asset Advisors, LLC holds $1,842,784,374 across 87 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
3,750,000 | $132,712,500 | |
| 2 | APGE |
Apogee Therapeutics, Inc.
|
987,000 | $131,004,510 | |
| 3 | SYRE |
Spyre Therapeutics, Inc.
|
1,279,134 | $113,561,516 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
|
1,595,000 | $96,274,200 | |
| 5 | ERAS |
Erasca, Inc.
|
5,250,000 | $96,180,000 | |
| 6 | INSM |
INSMED Inc
|
650,000 | $69,303,000 | |
| 7 | PRAX |
Praxis Precision Medicines, Inc.
|
185,000 | $61,936,150 | |
| 8 | ORKA |
Oruka Therapeutics, Inc.
|
590,000 | $56,150,300 |
All Filings in OMER
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $13,421,463 | 1,411,300 | Put | Sole | 2026-08-13 | |
| 2025-09-30 | $4,648,990 | 1,133,900 | Put | Sole | 2025-11-13 | |
| 2025-06-30 | $942,000 | 314,000 | Put | Sole | 2025-08-13 | |
| 2025-03-31 | $81,854 | 9,958 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $98,385 | 9,958 | Shares | Sole | 2025-02-13 | |
| No filing history on record for this holder in this stock. | ||||||